骶髂关节复合体疼痛多学科国际共识实践指南
BACKGROUND: The past two decades have witnessed tremendous growth in the appreciation and treatment of sacroiliac joint (SIJ) complex pain, including anatomical dissections that shed light on innervation, an appreciation for the contribution of extra-articular components to SIJ c…
要点
- 体格检查敏感但特异性低,阴性预测值更高;关节内注射对关节内疼痛有诊断价值。
- 关节外皮质类固醇注射短期缓解证据略强;骶外侧支射频消融对关节外病变可缓解至少6个月。
- 诊断性阻滞阳性阈值常为50%,治疗性结局可接受≥30%疼痛缓解或非疼痛指标改善。
核心结论
- 骶髂关节复合体疼痛是慢性下腰痛的重要来源,影响15%至30%的轴性疼痛患者,疼痛主要位于L5以下。
主要发现
- 委员会对所有21个问题达成完全共识,21个组织正式认可指南。
- 体格检查对关节内疼痛有合理敏感性但特异性较低,阴性测试预测价值更高。
- 关节内和关节外病理患病率相当,关节内和关节外类固醇注射在精选患者中均可提供至少4周缓解。
- 骶外侧支射频消融对关节外病理提供至少6个月缓解的证据强,较大损伤或更积极消融策略证据更强。
关键数值与推荐
- 正式推荐需≥75%共识,推荐备注需>50%同意。
- 诊断或预后阻滞阳性截断值最常设为50%,治疗性结局支持≥30%疼痛缓解或非疼痛指标有意义改善。
- 弱证据支持葡萄糖增生疗法和富血小板血浆提供至少3个月疼痛缓解。
- 弱证据支持非甾体抗炎药预防射频消融后神经炎,多数情况下围术期无需停用抗凝。
- 对于经控制性阻滞确诊关节内疼痛且保守治疗失败的患者,弱或极弱证据支持微创骶髂关节融合可提供至少1年获益。
临床怎么用
- 应基于病史、体格检查和诊断性阻滞综合评估骶髂关节复合体疼痛,注意关节内与关节外成分。
- 对关节外病变可考虑骶外侧支射频消融,采用较大损伤策略可能更有效。
- 诊断性阻滞阳性阈值常取50%,治疗决策可结合≥30%疼痛缓解或功能改善等非疼痛指标。
局限性
- 许多问题的答案受限于低质量证据,需要更好研究。
- 非介入治疗证据多为间接外推自下腰痛研究。
- 三个学会对射频消融和融合术前阻滞标准有异议,一个学会对关节外注射证据更强声明弃权。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The past two decades have witnessed tremendous growth in the appreciation and treatment of sacroiliac joint (SIJ) complex pain, including anatomical dissections that shed light on innervation, an appreciation for the contribution of extra-articular components to SIJ complex pain, the advent of radiofrequency ablation (RFA) and a host of minimally-invasive surgical techniques. Yet, there is no standardization of diagnosis and treatment paradigms. METHODS: In February 2023, the Boards of Directors for the American Academy of Pain Medicine (AAPM) and American Society of Regional Anesthesia & Pain Medicine (ASRA-PM) approved the development of multispecialty guidelines on SIJ complex pain. Thirty partner organizations with clinical and scientific interests in SIJ complex pain were identified, and formal letters of request-for-participation were sent to each, along with a request for nominees to serve on the committee. Twenty five organizations agreed to participate in addition to the Departments of Defense and Veterans Affairs. A steering committee developed 21 questions, which spanned criteria for diagnosis, non-interventional and interventional treatments including surgery, technical parameters on how to optimize results, and what constitutes positive outcomes. Questions were methodically assigned to specialized modules comprising 4-5 members with complementary expertise, who collaborated with the Subcommittee Lead and one of three Committee Chairs to develop preliminary drafts. Following thorough revisions, these drafts were subsequently submitted to the full committee for comprehensive review. A modified Delphi method was used in which the answers to questions were sent to the committee en bloc and comments were returned in a non-blinded fashion to the Chairs, who incorporated the comments and sent out revised versions until consensus was achieved. During a committee meeting before commencement, it was agreed that recommendations would be noted when there was >50% agreement among committee members, but that a formal recommendation would require ≥75% consensus. RESULTS: Twenty-one organizations formally endorsed the guidelines. The American Society of Anesthesiologists, and American Academy of Physical Medicine & Rehabilitation, and the North American Spine Society affirmed the benefit of the guidelines but did not officially endorse them. The American Academy of Neurology declined to affirm the benefit of the guidelines citing 'lack of relevance to their membership.' Per policies, while the Departments of Defense and Veterans Affairs did not formally review the guidelines for endorsement, their representatives approved them. In addition to being endorsed or the benefit affirmed by all voting organizations, complete consensus from committee members was obtained on all 21 questions. On two recommendations, there were dissensions from three societies who thought that selecting patients for sacral lateral branch RFA and minimally-invasive fusion should be based on ≥75% relief from two blocks instead of at least 50% relief from a single block before RFA, and greater than 50% pain relief with documented functional improvement after a single block before fusion. One additional society (Latin American Society of Regional Anesthesia) abstained on the statement that the evidence is stronger for extra-articular than intra-articular injections. The committee found that a battery of physical exam tests has reasonable sensitivity, but lower specificity, for identifying intra-articular but not extra-articular pain, with negative tests having greater predictive value than positive ones. Intra-articular injections have diagnostic validity for SIJ intra-articular, but not extra-articular, pain. There is unclear or negative evidence for imaging. The prevalence rates of intra-articular and extra-articular pathology are comparable, with both intra- and extra-articular steroid injections providing at least 4 weeks of relief in well-selected patients. However, the evidence is slightly stronger for extra-articular corticosteroid injections to provide short-term relief. The evidence base for non-interventional therapies is indirect, extrapolated mostly from low back pain studies. There is weak evidence supporting dextrose-based prolotherapy and platelet-rich plasma to provide at least 3 months of pain relief. There is strong evidence for sacral lateral branch RFA to provide relief for at least 6 months in individuals with extra-articular pathology, with face validity and indirect evidence from randomized trials supporting sacral lateral branch blocks as a prognostic tool. There is stronger evidence for larger lesions or more aggressive lesioning strategies than for less stringent techniques. There is weak evidence to support non-steroidal anti-inflammatory drugs to prevent neuritis after RFA, and in most cases anticoagulation does not require cessation in the periprocedural period. With an aggressive lesioning strategy, sensory stimulation provides minimal therapeutic benefit, with weak, extrapolated evidence that motor stimulation can provide safety benefit. The cut-off to designate diagnostic or prognostic blocks as positive is most commonly set at 50%, with higher values not shown to improve outcomes for more definitive procedures; for therapeutic treatment outcomes, the evidence supports a lower threshold of ≥30% pain relief or meaningful benefit on non-pain outcomes (eg, opioid cessation) for designation of a positive response. For carefully selected patients with intra-articular SIJ complex pain based on controlled blocks who have failed conservative therapies, there is weak or very weak evidence that minimally invasive SIJ fusion can provide benefit for at least one year. CONCLUSIONS: SIJ complex pain remains an underappreciated source of chronic low back pain, affecting between 15% and 30% of patients with axial pain predominantly below L5. Answers to many questions were limited by low-quality evidence, indicating the need for better research. SIJ complex pain is a multifarious condition (ie, pain can be from different portions of both the intra- and extra-articular components of the joint) for which an interdisciplinary, multimodal treatment plan can optimize treatment outcomes.
引用
- McCormick ZL, Hurley RW, Anitescu M, et al. Consensus practice guidelines on sacroiliac joint complex pain from a multispecialty, international working group. Reg Anesth Pain Med. 2025. PMID: 41320235. doi:10.1136/rapm-2025-107387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。